SCHEMBL3608441

SCHEMBL3608441

CC(C)(C)OC(=O)CNS(=O)(=O)c1ccc(-c2ccc(NC(=O)c3cc4ccccc4o3)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.74
MMP14 P50281 2/20 0.74
MMP13 P45452 3/20 0.59
ADAMTS4 O75173 1/20 0.59
MMP7 P09237 1/20 0.59
MMP12 P39900 1/20 0.59
NPC1 O15118 7/20 0.56
RAB9A P51151 7/20 0.56
LMNA P02545 2/20 0.56
CLK1 P49759 1/20 0.56
SMN1; SMN2 Q16637 5/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPT P10636 4/20 0.52
TP53 P04637 3/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
TSHR P16473 2/20 0.52
KDM4E B2RXH2 1/20 0.52
ATM Q13315 1/20 0.52
HSD17B10 Q99714 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3615340 0.85 MMP2 (1.00) MMP2MMP14MMP13ADAMTS4MMP7
SCHEMBL3621198 0.84 MMP2 (0.77) MMP2MMP14MMP13ADAMTS4MMP7
SCHEMBL27593754 0.84 MMP2 (0.77) MMP2MMP14MMP13ADAMTS4MMP7
SCHEMBL3611858 0.84 MMP2 (0.77) MMP2MMP14MMP13ADAMTS4MMP7
SCHEMBL3611458 0.81 MMP2 (0.77) MMP2MMP14MMP13ADAMTS4MMP7
SCHEMBL7666345 0.80 LMNA (0.57) MMP12LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL3614192 0.80 MMP2 (0.68) MMP2MMP14MMP13ADAMTS4MMP7
SCHEMBL7663141 0.79 GPR27 (0.59) NPC1RAB9ALMNAALDH1A1MAPT
SCHEMBL7667729 0.78 ALDH1A1 (0.61) NPC1RAB9ALMNASMN1; SMN2ALDH1A1
SCHEMBL7582747 0.78 LMNA (0.65) MMP2LMNASMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same WYETH (US) 2010-06-03 US disclosed
EP-1692124-B1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH CORP (US) 2008-10-15 EP disclosed
US-7420001-B2 Biaryl sulfonamides and methods for using same WYETH (US) 2008-09-02 US disclosed
US-20050143422-A1 Biaryl sulfonamides and methods for using same WYETH (US) 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same STS, MMP3, AADAC MMP2 5/4885MMP14 19/4885MMP13 13/4885
US-20050143422-A1 Biaryl sulfonamides and methods for using same STS, MMP3, AADAC MMP2 5/4885MMP14 19/4885MMP13 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.